General Information:

Id: 3,917
Diseases: Diabetes mellitus, type II - [OMIM]
Insulin resistance
Homo sapiens
article
Reference: Koh KK et al.(2010) Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients J. Am. Coll. Cardiol. 55: 1209-1216 [PMID: 20298928]

Interaction Information:

Comment Atorvastatin 10, 20, 40, and 80 mg significantly reduced LDL cholesterol and apolipoprotein B levels after 2 months of therapy when compared with either baseline or placebo. Atorvastatin 10, 20, 40, and 80 mg significantly increased fasting plasma insulin and glycated hemoglobin levels when compared with either baseline or placebo. Atorvastatin 10, 20, 40, and 80 mg decreased insulin sensitivity when compared with either baseline or placebo. Despite beneficial reductions in LDL cholesterol and apolipoprotein B, atorvastatin treatment resulted in significant increases in fasting insulin and glycated hemoglobin levels consistent with insulin resistance and increased ambient glycemia in hypercholesterolemic patients.
Formal Description
Interaction-ID: 39760

drug/chemical compound

Atorvastatin

decreases_activity of

complex/PPI

LDL

in blood plasma
Drugbank entries Show/Hide entries for Atorvastatin
Comment Atorvastatin 10, 20, 40, and 80 mg significantly reduced LDL cholesterol and apolipoprotein B levels after 2 months of therapy when compared with either baseline or placebo. Atorvastatin 10, 20, 40, and 80 mg significantly increased fasting plasma insulin and glycated hemoglobin levels when compared with either baseline or placebo. Atorvastatin 10, 20, 40, and 80 mg decreased insulin sensitivity when compared with either baseline or placebo. Despite beneficial reductions in LDL cholesterol and apolipoprotein B, atorvastatin treatment resulted in significant increases in fasting insulin and glycated hemoglobin levels consistent with insulin resistance and increased ambient glycemia in hypercholesterolemic patients.
Formal Description
Interaction-ID: 39761

drug/chemical compound

Atorvastatin

decreases_quantity of

gene/protein

APOB

in blood plasma
Drugbank entries Show/Hide entries for Atorvastatin
Comment Atorvastatin 10, 20, 40, and 80 mg significantly reduced LDL cholesterol and apolipoprotein B levels after 2 months of therapy when compared with either baseline or placebo. Atorvastatin 10, 20, 40, and 80 mg significantly increased fasting plasma insulin and glycated hemoglobin levels when compared with either baseline or placebo. Atorvastatin 10, 20, 40, and 80 mg decreased insulin sensitivity when compared with either baseline or placebo. Despite beneficial reductions in LDL cholesterol and apolipoprotein B, atorvastatin treatment resulted in significant increases in fasting insulin and glycated hemoglobin levels consistent with insulin resistance and increased ambient glycemia in hypercholesterolemic patients.
Formal Description
Interaction-ID: 39762

drug/chemical compound

Atorvastatin

increases_activity of

in blood plasma; after fasting
Drugbank entries Show/Hide entries for Atorvastatin
Comment Atorvastatin 10, 20, 40, and 80 mg significantly reduced LDL cholesterol and apolipoprotein B levels after 2 months of therapy when compared with either baseline or placebo. Atorvastatin 10, 20, 40, and 80 mg significantly increased fasting plasma insulin and glycated hemoglobin levels when compared with either baseline or placebo. Atorvastatin 10, 20, 40, and 80 mg decreased insulin sensitivity when compared with either baseline or placebo. Despite beneficial reductions in LDL cholesterol and apolipoprotein B, atorvastatin treatment resulted in significant increases in fasting insulin and glycated hemoglobin levels consistent with insulin resistance and increased ambient glycemia in hypercholesterolemic patients.
Formal Description
Interaction-ID: 39770

drug/chemical compound

Atorvastatin

increases_quantity of

complex/PPI

Glycated hemoglobin

in blood plasma
Drugbank entries Show/Hide entries for Atorvastatin
Comment Atorvastatin 10, 20, 40, and 80 mg significantly reduced LDL cholesterol and apolipoprotein B levels after 2 months of therapy when compared with either baseline or placebo. Atorvastatin 10, 20, 40, and 80 mg significantly increased fasting plasma insulin and glycated hemoglobin levels when compared with either baseline or placebo. Atorvastatin 10, 20, 40, and 80 mg decreased insulin sensitivity when compared with either baseline or placebo. Despite beneficial reductions in LDL cholesterol and apolipoprotein B, atorvastatin treatment resulted in significant increases in fasting insulin and glycated hemoglobin levels consistent with insulin resistance and increased ambient glycemia in hypercholesterolemic patients.
Formal Description
Interaction-ID: 39771

drug/chemical compound

Atorvastatin

increases_activity of

phenotype

decreased insulin sensitivity

Drugbank entries Show/Hide entries for Atorvastatin
Comment Atorvastatin 10, 20, 40, and 80 mg significantly reduced LDL cholesterol and apolipoprotein B levels after 2 months of therapy when compared with either baseline or placebo. Atorvastatin 10, 20, 40, and 80 mg significantly increased fasting plasma insulin and glycated hemoglobin levels when compared with either baseline or placebo. Atorvastatin 10, 20, 40, and 80 mg decreased insulin sensitivity when compared with either baseline or placebo. Despite beneficial reductions in LDL cholesterol and apolipoprotein B, atorvastatin treatment resulted in significant increases in fasting insulin and glycated hemoglobin levels consistent with insulin resistance and increased ambient glycemia in hypercholesterolemic patients.
Formal Description
Interaction-ID: 39772

drug/chemical compound

Atorvastatin

increases_activity of

disease

Insulin resistance

Drugbank entries Show/Hide entries for Atorvastatin